Literature DB >> 20831872

Loop-swapped chimeras of the agouti-related protein and the agouti signaling protein identify contacts required for melanocortin 1 receptor selectivity and antagonism.

Mira P Patel1, Camila S Cribb Fabersunne, Ying-Kui Yang, Christopher B Kaelin, Gregory S Barsh, Glenn L Millhauser.   

Abstract

Agouti-related protein (AgRP) and agouti signaling protein (ASIP) are homologs that play critical roles in energy balance and pigmentation, respectively, by functioning as antagonistic ligands at their cognate melanocortin receptors. Signaling specificity is mediated in part through receptor binding selectivity brought about by alterations in the cysteine-rich carboxy-terminal domains of the ligands. AgRP binds with high affinity to the melanocortin 3 receptor and the melanocortin 4 receptor, but not to the melanocortin 1 receptor (MC1R), whereas ASIP binds with high affinity to all three receptors. This work explores the structural basis for receptor selectivity by studying chimeric proteins developed by interchanging loops between the cysteine-rich domain of ASIP and the cysteine-rich domain of AgRP. Binding data demonstrate that melanocortin 4 receptor responds to all chimeras and is therefore highly tolerant of gross loop changes. By contrast, MC1R responds primarily to those chimeras with a sequence close to that of wild-type ASIP. Further analysis of binding and functional data suggests that the ASIP C-terminal loop (a six-amino-acid segment closed by the final disulfide bond) is essential for high-affinity MC1R binding and inverse agonism. Comparison with previously published molecular models suggests that this loop makes contact with the first extracellular loop of MC1R through a series of key hydrophobic interactions.
Copyright © 2010 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20831872      PMCID: PMC2972358          DOI: 10.1016/j.jmb.2010.08.054

Source DB:  PubMed          Journal:  J Mol Biol        ISSN: 0022-2836            Impact factor:   5.469


  48 in total

Review 1.  New aspects on the melanocortins and their receptors.

Authors:  J E Wikberg; R Muceniece; I Mandrika; P Prusis; J Lindblom; C Post; A Skottner
Journal:  Pharmacol Res       Date:  2000-11       Impact factor: 7.658

Review 2.  The cystine knot motif in toxins and implications for drug design.

Authors:  D J Craik; N L Daly; C Waine
Journal:  Toxicon       Date:  2001-01       Impact factor: 3.033

Review 3.  Melanocortin receptors: their functions and regulation by physiological agonists and antagonists.

Authors:  Z A Abdel-Malek
Journal:  Cell Mol Life Sci       Date:  2001-03       Impact factor: 9.261

4.  Structure activity studies of the melanocortin-4 receptor by in vitro mutagenesis: identification of agouti-related protein (AGRP), melanocortin agonist and synthetic peptide antagonist interaction determinants.

Authors:  C Haskell-Luevano; R D Cone; E K Monck; Y P Wan
Journal:  Biochemistry       Date:  2001-05-22       Impact factor: 3.162

Review 5.  The melanocortin system.

Authors:  Ira Gantz; Tung M Fong
Journal:  Am J Physiol Endocrinol Metab       Date:  2003-03       Impact factor: 4.310

Review 6.  Functions for pro-opiomelanocortin-derived peptides in obesity and diabetes.

Authors:  Kathleen G Mountjoy
Journal:  Biochem J       Date:  2010-05-27       Impact factor: 3.857

7.  The agouti-related protein decapeptide (Yc[CRFFNAFC]Y) possesses agonist activity at the murine melanocortin-1 receptor.

Authors:  C Haskell-Luevano; E K Monck; Y P Wan; A M Schentrup
Journal:  Peptides       Date:  2000-05       Impact factor: 3.750

8.  Functional characterization of mutations in melanocortin-4 receptor associated with human obesity.

Authors:  G Ho; R G MacKenzie
Journal:  J Biol Chem       Date:  1999-12-10       Impact factor: 5.157

9.  High-resolution NMR structure of the chemically-synthesized melanocortin receptor binding domain AGRP(87-132) of the agouti-related protein.

Authors:  J C McNulty; D A Thompson; K A Bolin; J Wilken; G S Barsh; G L Millhauser
Journal:  Biochemistry       Date:  2001-12-25       Impact factor: 3.162

10.  Design, pharmacology, and NMR structure of a minimized cystine knot with agouti-related protein activity.

Authors:  Pilgrim J Jackson; Joseph C McNulty; Ying-Kui Yang; Darren A Thompson; Biaoxin Chai; Ira Gantz; Gregory S Barsh; Glenn L Millhauser
Journal:  Biochemistry       Date:  2002-06-18       Impact factor: 3.162

View more
  12 in total

1.  Agouti-related protein segments outside of the receptor binding core are required for enhanced short- and long-term feeding stimulation.

Authors:  Michael E Madonna; Jennifer Schurdak; Ying-Kui Yang; Stephen Benoit; Glenn L Millhauser
Journal:  ACS Chem Biol       Date:  2011-12-30       Impact factor: 5.100

2.  Mechanism of N-terminal modulation of activity at the melanocortin-4 receptor GPCR.

Authors:  Baran A Ersoy; Leonardo Pardo; Sumei Zhang; Darren A Thompson; Glenn Millhauser; Cedric Govaerts; Christian Vaisse
Journal:  Nat Chem Biol       Date:  2012-06-24       Impact factor: 15.040

3.  An unusual conformation of γ-melanocyte-stimulating hormone analogues leads to a selective human melanocortin 1 receptor antagonist for targeting melanoma cells.

Authors:  Minying Cai; Magda Stankova; Dhanasekaran Muthu; Alexander Mayorov; Zhehui Yang; Devendra Trivedi; Christopher Cabello; Victor J Hruby
Journal:  Biochemistry       Date:  2013-01-15       Impact factor: 3.162

4.  Structure-Activity Relationship Studies of a Macrocyclic AGRP-Mimetic Scaffold c[Pro-Arg-Phe-Phe-Asn-Ala-Phe-DPro] Yield Potent and Selective Melanocortin-4 Receptor Antagonists and Melanocortin-5 Receptor Inverse Agonists That Increase Food Intake in Mice.

Authors:  Katlyn A Fleming; Mark D Ericson; Katie T Freeman; Danielle N Adank; Mary M Lunzer; Stacey L Wilber; Carrie Haskell-Luevano
Journal:  ACS Chem Neurosci       Date:  2018-02-13       Impact factor: 4.418

5.  Incorporation of Agouti-Related Protein (AgRP) Human Single Nucleotide Polymorphisms (SNPs) in the AgRP-Derived Macrocyclic Scaffold c[Pro-Arg-Phe-Phe-Asn-Ala-Phe-dPro] Decreases Melanocortin-4 Receptor Antagonist Potency and Results in the Discovery of Melanocortin-5 Receptor Antagonists.

Authors:  Zoe M Koerperich; Mark D Ericson; Katie T Freeman; Robert C Speth; Irina D Pogozheva; Henry I Mosberg; Carrie Haskell-Luevano
Journal:  J Med Chem       Date:  2020-01-06       Impact factor: 7.446

6.  Targeting protein-trafficking pathways alters melanoma treatment sensitivity.

Authors:  Zhi-ming Huang; Milka Chinen; Philip J Chang; Tong Xie; Lily Zhong; Stephanie Demetriou; Mira P Patel; Rebecca Scherzer; Elena V Sviderskaya; Dorothy C Bennett; Glenn L Millhauser; Dennis H Oh; James E Cleaver; Maria L Wei
Journal:  Proc Natl Acad Sci U S A       Date:  2011-12-27       Impact factor: 11.205

7.  Structure-Activity Relationship Studies on a Macrocyclic Agouti-Related Protein (AGRP) Scaffold Reveal Agouti Signaling Protein (ASP) Residue Substitutions Maintain Melanocortin-4 Receptor Antagonist Potency and Result in Inverse Agonist Pharmacology at the Melanocortin-5 Receptor.

Authors:  Mark D Ericson; Katie T Freeman; Sathya M Schnell; Katlyn A Fleming; Carrie Haskell-Luevano
Journal:  J Med Chem       Date:  2017-10-04       Impact factor: 7.446

Review 8.  Bench-top to clinical therapies: A review of melanocortin ligands from 1954 to 2016.

Authors:  Mark D Ericson; Cody J Lensing; Katlyn A Fleming; Katherine N Schlasner; Skye R Doering; Carrie Haskell-Luevano
Journal:  Biochim Biophys Acta Mol Basis Dis       Date:  2017-03-29       Impact factor: 5.187

Review 9.  MC1R, the cAMP pathway, and the response to solar UV: extending the horizon beyond pigmentation.

Authors:  Jose C García-Borrón; Zalfa Abdel-Malek; Celia Jiménez-Cervantes
Journal:  Pigment Cell Melanoma Res       Date:  2014-05-30       Impact factor: 4.693

10.  Transient ectopic overexpression of agouti-signalling protein 1 (asip1) induces pigment anomalies in flatfish.

Authors:  Raúl Guillot; Rosa Maria Ceinos; Rosa Cal; Josep Rotllant; José Miguel Cerdá-Reverter
Journal:  PLoS One       Date:  2012-12-10       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.